Deletion of 18q is a strong and independent prognostic feature in prostate cancer
Standard
Deletion of 18q is a strong and independent prognostic feature in prostate cancer. / Kluth, Martina; Graunke, Maximilian ; Koop, Christina; Hube-Magg, Claudia; Minner, Sarah; Michl, Uwe; Graefen, Markus; Huland, Hartwig; Pompe, Raisa; Jacobsen, Frank; Hinsch, Andrea; Wittmer, Corinna; Lebok, Patrick; Steurer, Stefan; Büscheck, Franziska; Clauditz, Till; Wilczak, Waldemar; Sauter, Guido; Schlomm, Thorsten; Simon, Ronald.
In: ONCOTARGET, Vol. 7, No. 52, 27.12.2016, p. 86339-86349.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Deletion of 18q is a strong and independent prognostic feature in prostate cancer
AU - Kluth, Martina
AU - Graunke, Maximilian
AU - Koop, Christina
AU - Hube-Magg, Claudia
AU - Minner, Sarah
AU - Michl, Uwe
AU - Graefen, Markus
AU - Huland, Hartwig
AU - Pompe, Raisa
AU - Jacobsen, Frank
AU - Hinsch, Andrea
AU - Wittmer, Corinna
AU - Lebok, Patrick
AU - Steurer, Stefan
AU - Büscheck, Franziska
AU - Clauditz, Till
AU - Wilczak, Waldemar
AU - Sauter, Guido
AU - Schlomm, Thorsten
AU - Simon, Ronald
PY - 2016/12/27
Y1 - 2016/12/27
N2 - Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successfully analyzed cancers (7.5%). 18q deletion was linked to unfavorable tumor phenotype. An 18q deletion was seen in 6.4% of 4,360 pT2, 8.0% of 1,559 pT3a and 11.8% of 930 pT3b-pT4 cancers (P < 0.0001). Deletions of 18q were detected in 6.9% of 1,636 Gleason ≤ 3 + 3, 6.8% of 3,804 Gleason 3 + 4, 10.1% of 1,058 Gleason 4+3, and 9.9% of 344 Gleason ≥ 4 + 4 tumors (P = 0.0013). Deletions of 18q were slightly more frequent in ERG-fusion negative (8.2%) than in ERG-fusion positive cancers (6.4%, P = 0.0063). 18q deletions were also linked to biochemical recurrence (BCR, P < 0.0001). This was independent from established pre- and postoperative prognostic factors (P ≤ 0.0004). In summary, the results of our study identify 18q deletion as an independent prognostic parameter in prostate cancer. As it is easy to measure, 18q deletion may be a suitable component for multiparametric molecular prostate cancer prognosis tests.
AB - Deletion of 18q recurrently occurs in prostate cancer. To evaluate its clinical relevance, dual labeling fluorescence in-situ hybridization (FISH) using probes for 18q21 and centromere 18 was performed on a prostate cancer tissue microarray (TMA). An 18q deletion was found in 517 of 6,881 successfully analyzed cancers (7.5%). 18q deletion was linked to unfavorable tumor phenotype. An 18q deletion was seen in 6.4% of 4,360 pT2, 8.0% of 1,559 pT3a and 11.8% of 930 pT3b-pT4 cancers (P < 0.0001). Deletions of 18q were detected in 6.9% of 1,636 Gleason ≤ 3 + 3, 6.8% of 3,804 Gleason 3 + 4, 10.1% of 1,058 Gleason 4+3, and 9.9% of 344 Gleason ≥ 4 + 4 tumors (P = 0.0013). Deletions of 18q were slightly more frequent in ERG-fusion negative (8.2%) than in ERG-fusion positive cancers (6.4%, P = 0.0063). 18q deletions were also linked to biochemical recurrence (BCR, P < 0.0001). This was independent from established pre- and postoperative prognostic factors (P ≤ 0.0004). In summary, the results of our study identify 18q deletion as an independent prognostic parameter in prostate cancer. As it is easy to measure, 18q deletion may be a suitable component for multiparametric molecular prostate cancer prognosis tests.
U2 - 10.18632/oncotarget.13404
DO - 10.18632/oncotarget.13404
M3 - SCORING: Journal article
C2 - 27861151
VL - 7
SP - 86339
EP - 86349
JO - ONCOTARGET
JF - ONCOTARGET
SN - 1949-2553
IS - 52
ER -
